Detailed dose evidence documented for Oritavancin in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
Orbactiv: 1,200 mg IV single dose over 3 h. Kimyrsa: 1,200 mg IV single dose over 1 h. No dose adjustment needed for mild or moderate renal or hepatic impairment (severe impairment not evaluated).
Not established
What is not established
Repeated dosing for complicated infections (studied but not FDA-approved).
Pediatric use (not approved).
Osteomyelitis, endocarditis, or prosthetic joint infections (off-label only).